Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2018-04-27
Summary
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the ATU setting.
Conditions
Interventions
- OTHER
-
Non-interventional
Non-interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-20
- Primary Completion
- 2018-02-20
- Completion
- 2018-02-20
Countries
- France
Study Locations
More Related Trials
-
Post-ATU Study of Nivolumab
NCT03325257 ·Status: COMPLETED
-
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
NCT03696069 ·Status: COMPLETED
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
NCT02905266 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
NCT03771859 ·Status: ACTIVE_NOT_RECRUITING
-
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
NCT03313206 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
NCT02553642 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
NCT02599402 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
NCT04146324 ·Status: COMPLETED
-
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
NCT03724968 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
NCT04495010 ·Status: WITHDRAWN ·Phase: PHASE2
-
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
NCT05527795 ·Status: RECRUITING
-
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
NCT05002569 ·Status: TERMINATED ·Phase: PHASE3
-
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
NCT03732560 ·Status: COMPLETED
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
NCT01721772 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED
-
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
NCT03374839 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
NCT02388906 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
NCT03329846 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
NCT02714218 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
NCT06586593 ·Status: RECRUITING